Volume 2, Issue 3, May 2014, Page: 27-32
Clinical Significance of HOX11L2 and HOX11 Gene Expression in T-ALL Patients
Said H. Abdu, Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt
Doaa Shahin, Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Mohamed R. El-Shanshory, Department of Pediatric, Faculty of Medicine, Tanta University, Tanta, Egypt
Hoda A. Salem, Department of Clinical Pharmacy, Faculty of pharmacy, Misr University for Science and Technology, Cairo, Egypt
Eman A. Amer, Biochemistry Department, Faculty of pharmacy, Modern Science and Art University, Cairo, Egypt
Mohamed M. El-Shebeiny, Department of Clinical Oncology, Faculty of Medicine, Tanta University, Tanta, Egypt
Received: May 24, 2014;       Accepted: Jun. 14, 2014;       Published: Jul. 20, 2014
DOI: 10.11648/j.jctr.20140203.12      View  3265      Downloads  198
Abstract
Objective: The aim of this study was to determine the prognostic value of two structurally related homeobox genes TLX1/HOX11 and TLX3/HOX11L2 on the clinical outcome of T-ALL patients. Material and Methods: The study included 28 newly diagnosed T-ALL patients. HOX11L2 and HOX11 gene expression were detected by real time PCR. Patients received treatment according to the ALL BFM-90 protocol. Results: Of 28 patients, 8(28.6%) expressed HOX11L2 and 4(14.3%) expressed HOX11.The overall survival of patients with HOX11L2 expression was lower than of the patients without HOX11L2 expression (log-rank P<0.025). As regards HOX11 expression, a statistically significant difference in clinical outcome was found, where HOX11 expression conferred a prognostic advantage (p< 0.001). Conclusion: the present study was showed that the outcome of HOX11L2 and HOX11 expression differs, with poor outcome for patients with HOX11l2-expression. Future molecular diagnostics may make use of such leukemia-specific markers as HOX11L2 and HOX11 to detect minimal residual disease.
Keywords
HOX11L2, HOX11, Real Time PCR, T-ALL
To cite this article
Said H. Abdu, Doaa Shahin, Mohamed R. El-Shanshory, Hoda A. Salem, Eman A. Amer, Mohamed M. El-Shebeiny, Clinical Significance of HOX11L2 and HOX11 Gene Expression in T-ALL Patients, Journal of Cancer Treatment and Research. Vol. 2, No. 3, 2014, pp. 27-32. doi: 10.11648/j.jctr.20140203.12
Reference
[1]
Chiaretti S., and Foa R.: T-cell Acute lymphoblastic leukemia. Haematologica 2009; 94 (2):160-162.
[2]
Thiel E., Kranze B.R., Raghavcher A., Bartran C.R., Loffler H. et al.: Prethymic phenotype and genotype of pre-T (CD7+/ER-) – cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 1989; 73:1247-1258.
[3]
Silverman L.B., Gelber R.D., Dalton V.K., Asselin B.L., Barr R.D. et al.: Improved outcome for children with acute lymphobalstic leukemia: results of Dane-Faber consortium protocol 91-01. Blood 2001; 97, 1211-1218.
[4]
Harrison C.T. and Foronil L. : Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev Clin Exp Hematol.2002; 3:91-113.
[5]
Cauwelier B., Dastugue N., Cools J., Poppe B., Herens C. et al.: Molecular cytogenetics study of 126 unselected T-ALL cases reveals high incidence of Tc beta locus rearrangements and putative new T-cell oncogenes. Leukemia 2006; 20:1238-1244.
[6]
Carrol A.J., Crist W.M., Ragab A.H. et al.: The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 76:1220-4.
[7]
Speleman F., Cauwelier B., Dastugue N., Cools J. et al.: A new recurrent inversion, inv(7)(p15q34), leads to transcription al activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia 2005; 19:358-66.
[8]
Hatano M., Roberts C.W., Minden M., Crist W.M. et al.: Deregulation of a homeopox gene HOX11 by the t(10;14)in T-cell leukemia. Science 1991; 253: 79-82.
[9]
Bernard O.A., Busson-Leconiat M., Ballerini P., Mauchauffe M. et al.: A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the HOX11L2 gene in T acute lymphoblastic leukemia. Leukemia 2001; 15:1495-504.
[10]
Baldus. C.D, Thibaut .J, Goekbuget N., Stroux A., Schlee C., Mossner M., Burmeister T., Schwartz S., Bloomfield C.D., Hoelzer D., Thiel E. and Hofmann W.K.: Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica 2009;94:1383-1390
[11]
Asnafi V., Radford Weiss L., Dastugue N., Bayle C. et al.: CALM-AFT10 is a common fusion transcript in T-ALL and is specific to the TCR gamma delta lineage. Blood 2003; 102:1000-1006.
[12]
Harrisan CJ : Cytogenetics of Pediatric and adolescent acute lymphoblastic leukemias. Br J Haematol 2009; 144(2):147-56.
[13]
ChenE, HuangX, ZhengY, Li Y, ChesneyA, Ben-David Y, Yang E, Hough MR: Phosphorylation of HOX11/TLX1 on Threonine-247 during mitosis modulates expression of cyclin B1. Molecular Cancer 2010; 9:246
[14]
Sekimizu M, Sunami S, Nakazawa A, Hayashi Y, Okimoto Y, Saito AM, Horibe K, Tsurusawa M, Mori T.:Chromosome abnormalities in advanced stage T-cell lymphoblastic lymphoma of children and adolescents: a report from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) and review of the literature. Br J Haematol. 2011;154(5):612-7
[15]
Bene M.C., Castoldi G., Krapp W., Ludwig W.D. Matutes E. et al.: Proposals for the immunological classification of acute leukemia. European Group for the immunological characteristics of leukemia (EGIL). Leukemia1995; 9:1783-6.
[16]
Schrappe M., Reiter A., Ludwig W., Harbott J., Zimmermann M. et al.: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 2000; 95(11): 3310-22.
[17]
Baldus C.D., Martus P., Burmeister T., Schwartz S., Gokbuget N. et al.: Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J of Clinical Oncology 2007; 25; 24: 3739-3745.
[18]
Ballerini P., Blaise A., Busson-Le Coiant M. et al.: HOX11L2 expression defining a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 2002; 100:991-997.
[19]
Martin Val, Grotel J.P.P., Meijerink H., Berna Beverloo et al.: The outcome of molecular- cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia retrospective study of patients treated according to DCOG or COALL protocols. Haematologica 2006 ; 91(9)1212-21
[20]
Mauvieux L., Leymarie V., Helias C., Perrusson N. et al. : High incidence of HOX11L2 expression in children with T-ALL. Leukemia 2002; 16(12):2417-22.
[21]
Bergeron J., Clappier E., Radford I., Buzyn A., Millien C. et al.: Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-Alls. Blood 2007; 110(7):2324-30.
[22]
Dear T.N., Sanchez-Garcia I., Rabbits T.H. : The HOX11 gene encodes a DNA –binding nuclear transcription factor belonging to a distinct family of homeopox genes. Proc Natl Acad USA 1993; 90: 4431-4435.
[23]
Kenndy M.A., Gonzalez-Sarmiento R., Kees U.R., Lampert F. et al.: HOX11, a homeopox-containing T-cell oncogene on human chromosome 10q24. Proc Nat Acad Sci USA 1991; 88:8900-04.
[24]
Ferrnado A.A., Neuberg D.S., Hams D.O., Staunton J., Loh M.L. et al. : Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1:75-87.
[25]
Cave H., Suciu S., Preudhomme C., Popper B., Robert A. et al.: Clinical Significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: Blood 2004; 103:442-50.
[26]
Gottardo N.G., Jacoby P.A., Sather H.N., Reaman G.H. et al.: Significance of HOX11L2/TLX3 expression in children with T-cell acute lymphoblastic leukemia treated on children's cancer group protocols. Leukemia 2005; 19:1705-8.
[27]
Berger R., Dastugue N., Busson M., Van Den J., Perot C. et al.: t(5;14)/HOX11L2 positive T-cell acute lymphoblastic leukemia. A collaborative study of the group Francais de Cytogenetique Hematologique (GFCH). Leukemia 2003; 17:1851-7.
[28]
Ferrnado A.A., Neuberg D.S., Dodge R.K., Paietta E. et al.: Prognostic significance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukemia.. Lancet 2004; 363: 535-6.
[29]
Ludwig W.D., Harbott J., Bartram C.R., Komische B., Sperling C. et al.: Incidence and prognostic significance of immunophenotyping subgroups in childhood acute lymphoblastic leukemia.: Experience of the BFM study 86. Recent Results Cancer Res 1993; 131:269-82.
[30]
Pullen J., Shuster J.J., Link M., Borowitz M., Amylon M. et al.: Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A pediatric Oncology Group (POG) study. Leukemia 1999; 13: 1696-707.
[31]
Asnafi V., Beljord K., Libura M., Villarese P., Millien C. et al.: Age related phenotypic and oncogeneic differences in T-cell acute lymphoblastic leukemia may reflect thymic atrophy. Blood 2004; 104: 4173-80.
[32]
Ballerini P., Landman-Parker J., Cayuela J., Asnafi V., Labopin P. et al.: Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome. Haematologica 2008; 93(11):1658-65.
Browse journals by subject